The 2.7 Å Crystal Structure of the Autoinhibited Human c-Fms Kinase Domain

Journal of Molecular Biology

Volumn 367, Issue 3, 2007, Pages 839-847

  Walter, Mark ^a   Lucet, Isabelle S ^a   Patel, Onisha ^a   Broughton, Sophie E ^a   Bamert, Rebecca ^a   Williams, Neal K ^a,b   Fantino, Emmanuelle ^b   Wilks, Andrew F ^b   Rossjohn, Jamie ^a  

^a Department of Physiology School of Biomedical Sciences   (Australia)

^b Cytopia Ltd   (Australia)

Author keywords

autoinhibitory mechanism; c Fms; Gleevec; macrophage colony stimulating factor receptor; receptor tyrosine kinase

Indexed keywords

COLONY STIMULATING FACTOR 1; IMATINIB; COLONY STIMULATING FACTOR RECEPTOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; RECOMBINANT PROTEIN;

ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CRYSTAL STRUCTURE; CYTOSOL; ENZYME INHIBITION; GENE CONTROL; GENE TARGETING; HUMAN; MONONUCLEAR CELL; ONCOGENE; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR BINDING; RHEUMATOID ARTHRITIS; AMINO ACID SEQUENCE; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; GENETICS; IN VITRO STUDY; MOLECULAR GENETICS; PROTEIN TERTIARY STRUCTURE; SEQUENCE HOMOLOGY; X RAY CRYSTALLOGRAPHY;

AMINO ACID SEQUENCE; CRYSTALLOGRAPHY, X-RAY; HUMANS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; PYRIMIDINES; RECEPTOR, MACROPHAGE COLONY-STIMULATING FACTOR; RECOMBINANT PROTEINS; SEQUENCE HOMOLOGY, AMINO ACID;

EID: 33847281812     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jmb.2007.01.036     Document Type: Article

References (51)

1. Sicheri F., Moarefi I., and Kuriyan J. Crystal structure of the Src family tyrosine kinase Hck. Nature 385 (1997) 602-609
2. Xu W., Harrison S.C., and Eck M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385 (1997) 595-602
3. Nagar B., Hantschel O., Young M.A., Scheffzek K., Veach D., Bornmann W., et al. Structural basis for the autoinhibition of c-Abl tyrosine kinase. Cell 112 (2003) 859-871
4. Saharinen P., Takaluoma K., and Silvennoinen O. Regulation of the Jak2 tyrosine kinase by its pseudokinase domain. Mol. Cell. Biol. 20 (2000) 3387-3395
5. Ullrich A., and Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 61 (1990) 203-212
6. Rosnet O., and Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit. Rev. Oncog. 4 (1993) 595-613
7. Griffith J., Black J., Faerman C., Swenson L., Wynn M., Lu F., et al. The structural basis for autoinhibition of FLT3 by the juxtamembrane domain. Mol. Cell 13 (2004) 169-178
8. Mol C.D., Dougan D.R., Schneider T.R., Skene R.J., Kraus M.L., Scheibe D.N., et al. Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase. J. Biol. Chem. 279 (2004) 31655-31663
9. Sherr C.J., Rettenmier C.W., Sacca R., Roussel M.F., Look A.T., and Stanley E.R. The c-fms proto-oncogene product is related to the receptor for the mononuclear phagocyte growth factor, CSF-1. Cell 41 (1985) 665-676
10. Donner L., Fedele L.A., Garon C.F., Anderson S.J., and Sherr C.J. McDonough feline sarcoma virus: characterization of the molecularly cloned provirus and its feline oncogene (v-fms). J. Virol. 41 (1982) 489-500
11. Stanley E.R., Guilbert L.J., Tushinski R.J., and Bartelmez S.H. CSF-1-a mononuclear phagocyte lineage-specific hemopoietic growth factor. J. Cell Biochem. 21 (1983) 151-159
12. Stanley E.R., and Heard P.M. Factors regulating macrophage production and growth. Purification and some properties of the colony stimulating factor from medium conditioned by mouse L cells. J. Biol. Chem. 252 (1977) 4305-4312
13. Barreda D.R., Hanington P.C., and Belosevic M. Regulation of myeloid development and function by colony stimulating factors. Dev. Comp. Immunol. 28 (2004) 509-554
14. Kacinski B.M. CSF-1 and its receptor in breast carcinomas and neoplasms of the female reproductive tract. Mol. Reprod. Dev. 46 (1997) 71-74
15. Aharinejad S., Abraham D., Paulus P., Abri H., Hofmann M., Grossschmidt K., et al. Colony-stimulating factor-1 antisense treatment suppresses growth of human tumor xenografts in mice. Cancer Res. 62 (2002) 5317-5324
16. Aharinejad S., Paulus P., Sioud M., Hofmann M., Zins K., Schafer R., et al. Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice. Cancer Res. 64 (2004) 5378-5384
17. Lin E.Y., Nguyen A.V., Russell R.G., and Pollard J.W. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J. Exp. Med. 193 (2001) 727-740
18. Wyckoff J., Wang W., Lin E.Y., Wang Y., Pixley F., Stanley E.R., et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 64 (2004) 7022-7029
19. Danks L., Sabokbar A., Gundle R., and Athanasou N.A. Synovial macrophage-osteoclast differentiation in inflammatory arthritis. Ann. Rheum. Dis. 61 (2002) 916-921
20. Isbel N.M., Nikolic-Paterson D.J., Hill P.A., Dowling J., and Atkins R.C. Local macrophage proliferation correlates with increased renal M-CSF expression in human glomerulonephritis. Nephrol. Dial. Transplant. 16 (2001) 1638-1647
21. Rosenfeld M.E., Yla-Herttuala S., Lipton B.A., Ord V.A., Witztum J.L., and Steinberg D. Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am. J. Pathol. 140 (1992) 291-300
22. Jose M.D., Le Meur Y., Atkins R.C., and Chadban S.J. Blockade of macrophage colony-stimulating factor reduces macrophage proliferation and accumulation in renal allograft rejection. Am. J. Transplant. 3 (2003) 294-300
23. McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin. Oncol. 31 (2004) 30-36
24. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl. J. Med. 347 (2002) 472-480
25. Dewar A.L., Cambareri A.C., Zannettino A.C., Miller B.L., Doherty K.V., Hughes T.P., and Lyons A.B. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood 105 (2005) 3127-3132
26. Dewar A.L., Domaschenz R.M., Doherty K.V., Hughes T.P., and Lyons A.B. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors. Leukemia 17 (2003) 1713-1721
27. Taylor G.R., Reedijk M., Rothwell V., Rohrschneider L., and Pawson T. The unique insert of cellular and viral fms protein tyrosine kinase domains is dispensable for enzymatic and transforming activities. EMBO J. 8 (1989) 2029-2037
28. Knighton D.R., Zheng J.H., Ten Eyck L.F., Xuong N.H., Taylor S.S., and Sowadski J.M. Structure of a peptide inhibitor bound to the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase. Science 253 (1991) 414-420
29. Hubbard S.R. Juxtamembrane autoinhibition in receptor tyrosine kinases. Nature Rev. Mol. Cell. Biol. 5 (2004) 464-471
30. Huse M., and Kuriyan J. The conformational plasticity of protein kinases. Cell 109 (2002) 275-282
31. Bourette R.P., and Rohrschneider L.R. Early events in M-CSF receptor signaling. Growth Factors 17 (2000) 155-166
32. Courtneidge S.A., Dhand R., Pilat D., Twamley G.M., Waterfield M.D., and Roussel M.F. Activation of Src family kinases by colony stimulating factor-1, and their association with its receptor. EMBO J. 12 (1993) 943-950
33. Irusta P.M., Luo Y., Bakht O., Lai C.C., Smith S.O., and DiMaio D. Definition of an inhibitory juxtamembrane WW-like domain in the platelet-derived growth factor beta receptor. J. Biol. Chem. 277 (2002) 38627-38634
34. Heiss E., Masson K., Sundberg C., Pedersen M., Sun J., Bengtsson S., and Ronnstrand L. Identification of Y589 and Y599 in the juxtamembrane domain of Flt3 as ligand-induced autophosphorylation sites involved in binding of Src family kinases and the protein tyrosine phosphatase SHP2. Blood 108 (2006) 1542-1550
35. Lennartsson J., Blume-Jensen P., Hermanson M., Ponten E., Carlberg M., and Ronnstrand L. Phosphorylation of Shc by Src family kinases is necessary for stem cell factor receptor/c-kit mediated activation of the Ras/MAP kinase pathway and c-fos induction. Oncogene 18 (1999) 5546-5553
36. Mori S., Ronnstrand L., Yokote K., Engstrom A., Courtneidge S.A., Claesson-Welsh L., and Heldin C.H. Identification of two juxtamembrane autophosphorylation sites in the PDGF beta-receptor; involvement in the interaction with Src family tyrosine kinases. EMBO J. 12 (1993) 2257-2264
37. Paniagua R.T., Sharpe O., Ho P.P., Chan S.M., Chang A., Higgins J.P., et al. Selective tyrosine kinase inhibition by imatinib mesylate for the treatment of autoimmune arthritis. J. Clin. Invest. 116 (2006) 2633-2642
38. Furitsu T., Tsujimura T., Tono T., Ikeda H., Kitayama H., Koshimizu U., et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92 (1993) 1736-1744
39. Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. 23 (2005) 5357-5364
40. Taylor J.R., Brownlow N., Domin J., and Dibb N.J. FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance. Oncogene 25 (2006) 147-151
41. Hubbard S.R., Wei L., Ellis L., and Hendrickson W.A. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature 372 (1994) 746-754
42. Lucet I.S., Fantino E., Styles M., Bamert R., Patel O., Broughton S.E., et al. The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107 (2006) 176-183
43. Liu Y., and Gray N.S. Rational design of inhibitors that bind to inactive kinase conformations. Nature Chem. Biol. 2 (2006) 358-364
44. Okram B., Nagle A., Adrian F.J., Lee C., Ren P., Wang X., et al. A general strategy for creating "inactive-conformation" abl inhibitors. Chem. Biol. 13 (2006) 779-786
45. Otwinowski Z., and Minor W. Processing of X-ray diffraction data collected in oscillation mode. Methods Enzymol. 276 (1997) 307-326
46. Collaborative Computational Project, no. 4. The CCP4 suite: programs for protein crystallography. Acta Crystallog. sect. D 50 (1994) 760-763
47. Potterton E., Briggs P., Turkenburg M., and Dodson E. A graphical user interface to the CCP4 program suite. Acta Crystallog. sect. D 59 (2003) 1131-1137
48. Murshudov G.N., Vagin A.A., and Dodson E.J. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallog. sect. D 53 (1997) 240-255
49. Emsley P., and Cowtan K. Coot: model-building tools for molecular graphics. Acta Crystallog. sect. D 60 (2004) 2126-2132
50. DeLano W. The PyMOL Molecular Graphics System (2002), De Lano Scientific, San Carlos, CA
51. Schubert C., Schalk-Hihi C., Struble G.T., Ma H.C., Petrounia I.P., Brandt B., et al. Crystal structure of the tyrosine kinase domain of colony-stimulating factor-1 receptor (cFMS) in complex with two inhibitors. J. Biol. Chem. (2006) doi:10.1074/jbc.M6081883200